Claims
- 1. A method of treating or preventing diseases of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of a neurotrophic factor, such that said disease of the eye is treated or prevented.
- 2. The method according to claim 1 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.
- 3. The method according to claim 1 wherein said neurotrophic factor is a FGF.
- 4. The method according to claim 3 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.
- 5. The method according to claim 1 wherein said disease of the eye is macular degeneration.
- 6. The method according to claim 1 wherein said disease of the eye is diabetic retinopathy.
- 7. The method according to claim 1 wherein said disease of the eye is an inherited retinal degeneration.
- 8. The method according to claim 7 wherein said inherited retinal degeneration is retinitis pigmentosa.
- 9. The method according to claim 1 wherein said disease of the eye is glaucoma.
- 10. The method according to claim 1 wherein said disease of the eye is a surgery-induced retinopathy.
- 11. The method according to claim 1 wherein said disease of the eye is retinal detachment.
- 12. The method according to claim 1 wherein said disease of the eye is a photic retinopathy.
- 13. The method according to claim 1 wherein said disease of the eye is a toxic retinopathy.
- 14. The method according to claim 1 wherein said disease of the eye is a trauma-induced retinopathy.
- 15. The method according to claim 1 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
- 16. The method according to claim 1 wherein said gene delivery vector is a recombinant adeno-associated viral vector.
- 17. A method of inhibiting neovascular disease of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of an anti-angiogenic factor, such that said neovascular disease of the eye is inhibited.
- 18. The method according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or, a single chain anti-VEGF antibody.
- 19. The method according to claim 17 wherein said neovascular disease of the eye is diabetic retinopathy, wet AMD, and retinopathy of prematurity.
- 20. The method according to claim 17 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
- 21. The method according to claim 17 wherein said gene delivery vector is a recombinant adeno-associated viral vector.
- 22. A gene delivery vector which directs the expression of a neurotrophic factor, or an anti-angiogenic factor.
- 23. The gene delivery vector according to claim 22 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.
- 24. The gene delivery vector according to claim 22 wherein said neurotrophic factor is a FGF.
- 25. The gene delivery vector according to claim 22 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.
- 26. The gene delivery vector according to claim 22 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or, a single chain anti-VEGF antibody.
- 27. The gene delivery vector according to claim 22 wherein said vector is generated from a retrovirus.
- 28. The gene delivery vector according to claim 27 wherein said retrovirus is HIV or FIV.
- 29. The gene delivery vector according to claim 22 wherein said vector is generated from a recombinant adeno-associated virus.
- 30. A non-human animal model of neovascularization of the eye, comprising an animal having an angiogenic transgene in the eye.
- 31. The non-human animal model according to claim 30 wherein said neovascularization is retinal neovascularization.
- 32. The non-human animal model according to claim 30 wherein said neovascularization is choroidal neovascularization.
- 33. The non-human animal model according to claim 30 wherein said animal is a mouse or rat.
- 34. The non-human animal model according to claim 30 wherein said angiogenic transgene encodes VEGF.
- 35. The non-human animal model according to claim 30 wherein said angiogenic transgene encodes an angiopoietin.
- 36. A method for making a non-human animal model of neovascularization of the eye, comprising administering to a non-human animal a gene delivery vector which directs the expression of an angiogenic transgene.
- 37. The method according to claim 36 wherein said gene delivery vector is administered subretinally.
- 38. The method according to claim 36 wherein said gene delivery vector is administered intravitreally.
- 39. The method according to claim 36 wherein said gene delivery vector is rAV or rAAV.
- 40. The method according to claim 36 wherein said angiogenic transgene is a nucleic acid molecule which encodes VEGF.
- 41. The method according to claim 36 wherein said angiogenic transgene is a nucleic acid molecule which encodes an angiopoietin.
- 42. A method for determining the ability of an anti-angiogenic factor to inhibit neovascularization of the eye, comprising: (a) administering to an animal model according to any one of claims 30 to 35 an anti-angiogenic factor, and (b) determining the ability of said anti-angiogenic factor to inhibit neovascularization of the eye.
- 43. The method according to claim 42 wherein said anti-angiogenic factor is administered subretinally.
- 44. The method according to claim 42 wherein said anti-angiogenic factor is administered intravitreally.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/525,956, filed Mar. 15, 2000, which application claims priority to U.S. Provisional Application No. 60/124,460, filed Mar. 15, 1999, and U.S. Provisional Application No. 60/174,984, filed Jan. 6, 2000, all of which applications are incorporated by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60124460 |
Mar 1999 |
US |
|
60174984 |
Jan 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09665493 |
Sep 2000 |
US |
Child |
10090983 |
Mar 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09525956 |
Mar 2000 |
US |
Child |
09665493 |
Sep 2000 |
US |